Cantor Fitzgerald Reaffirms “Overweight” Rating for Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating reissued by research analysts at Cantor Fitzgerald in a report released on Friday,Benzinga reports. They presently have a $170.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 28.31% from the stock’s current price.

Several other research firms also recently commented on ASND. Evercore ISI raised their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. Jefferies Financial Group raised their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. TD Cowen upped their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Bank of America upped their price target on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $193.08.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded up $8.21 during mid-day trading on Friday, hitting $132.49. The company’s stock had a trading volume of 263,025 shares, compared to its average volume of 444,789. The company has a 50 day moving average of $132.15 and a 200-day moving average of $132.80. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00. The stock has a market cap of $8.03 billion, a PE ratio of -14.23 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Large investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $2,936,000. Acuta Capital Partners LLC purchased a new stake in Ascendis Pharma A/S in the third quarter valued at about $3,136,000. Finepoint Capital LP boosted its holdings in Ascendis Pharma A/S by 0.4% in the third quarter. Finepoint Capital LP now owns 190,072 shares of the biotechnology company’s stock worth $28,380,000 after acquiring an additional 800 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Ascendis Pharma A/S by 49.5% during the third quarter. The Manufacturers Life Insurance Company now owns 71,307 shares of the biotechnology company’s stock worth $10,647,000 after acquiring an additional 23,595 shares during the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in shares of Ascendis Pharma A/S by 35.3% during the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after acquiring an additional 48,120 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.